143 related articles for article (PubMed ID: 26354928)
41. Making a mountain out of a molehill: NRAS, mosaicism, and large congenital nevi.
Gerami P; Paller AS
J Invest Dermatol; 2013 Sep; 133(9):2127-30. PubMed ID: 23949765
[TBL] [Abstract][Full Text] [Related]
42. Melanoma in congenital melanocytic naevi.
Kinsler VA; O'Hare P; Bulstrode N; Calonje JE; Chong WK; Hargrave D; Jacques T; Lomas D; Sebire NJ; Slater O
Br J Dermatol; 2017 May; 176(5):1131-1143. PubMed ID: 28078671
[TBL] [Abstract][Full Text] [Related]
43. Nras in melanoma: targeting the undruggable target.
Mandalà M; Merelli B; Massi D
Crit Rev Oncol Hematol; 2014 Nov; 92(2):107-22. PubMed ID: 24985059
[TBL] [Abstract][Full Text] [Related]
44. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
45. RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.
Laugier F; Finet-Benyair A; André J; Rachakonda PS; Kumar R; Bensussan A; Dumaz N
Oncotarget; 2015 Sep; 6(29):28120-31. PubMed ID: 26356562
[TBL] [Abstract][Full Text] [Related]
46. Spatiotemporal expression of NRAS and occurrence of giant congenital melanocytic nevi.
Aimaier R; Chung M; Zhu H; Yu Q
Exp Dermatol; 2022 Apr; 31(4):582-585. PubMed ID: 35020224
[TBL] [Abstract][Full Text] [Related]
47. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.
Qian L; Chen K; Wang C; Chen Z; Meng Z; Wang P
Clin Cancer Res; 2020 Jul; 26(13):3408-3419. PubMed ID: 32156748
[TBL] [Abstract][Full Text] [Related]
48. Prognostic role of NRAS isoforms in Chinese melanoma patients.
Yan J; Xu L; Yu J; Wu X; Dai J; Xu T; Yu H; Guo J; Kong Y
Melanoma Res; 2019 Jun; 29(3):263-269. PubMed ID: 30489482
[TBL] [Abstract][Full Text] [Related]
49. NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.
Angelino G; De Pasquale MD; De Sio L; Serra A; Massimi L; De Vito R; Marrazzo A; Lancella L; Carai A; Antonelli M; Giangaspero F; Gessi M; Menchini L; Scarciolla L; Longo D; Mastronuzzi A
BMC Cancer; 2016 Jul; 16():512. PubMed ID: 27439913
[TBL] [Abstract][Full Text] [Related]
50. Discovery of Clinically Used Octenidine as
Chen XC; Tang GX; Dai J; Dai LT; Wu TY; Li WW; Ou TM; Huang ZS; Tan JH; Chen SB
J Med Chem; 2023 Apr; 66(7):5171-5184. PubMed ID: 36961300
[TBL] [Abstract][Full Text] [Related]
51. Treatment of NRAS-mutant melanoma.
Johnson DB; Puzanov I
Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
[TBL] [Abstract][Full Text] [Related]
52. Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry.
Hale EK; Stein J; Ben-Porat L; Panageas KS; Eichenbaum MS; Marghoob AA; Osman I; Kopf AW; Polsky D
Br J Dermatol; 2005 Mar; 152(3):512-7. PubMed ID: 15787820
[TBL] [Abstract][Full Text] [Related]
53. α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid.
Xia Y; Chen J; Gong C; Chen H; Sun J
Med Sci Monit; 2016 Apr; 22():1360-7. PubMed ID: 27104669
[TBL] [Abstract][Full Text] [Related]
54. Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center's experience.
Lovett A; Maari C; Decarie JC; Marcoux D; McCuaig C; Hatami A; Savard P; Powell J
J Am Acad Dermatol; 2009 Nov; 61(5):766-74. PubMed ID: 19766348
[TBL] [Abstract][Full Text] [Related]
55. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
[TBL] [Abstract][Full Text] [Related]
56. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
57. The in-vitro spheroid culture induces a more highly differentiated but tumorigenic population from melanoma cell lines.
Mo J; Sun B; Zhao X; Gu Q; Dong X; Liu Z; Ma Y; Zhao N; Liu Y; Chi J; Sun R
Melanoma Res; 2013 Aug; 23(4):254-63. PubMed ID: 23752306
[TBL] [Abstract][Full Text] [Related]
58. Mosaic NRAS Q61R mutation in a child with giant congenital melanocytic naevus, epidermal naevus syndrome and hypophosphataemic rickets.
Ramesh R; Shaw N; Miles EK; Richard B; Colmenero I; Moss C
Clin Exp Dermatol; 2017 Jan; 42(1):75-79. PubMed ID: 27900779
[TBL] [Abstract][Full Text] [Related]
59. Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma.
Alon M; Emmanuel R; Qutob N; Bakhman A; Peshti V; Brodezki A; Bassan D; Kosloff M; Samuels Y
Pigment Cell Melanoma Res; 2018 Sep; 31(5):641-648. PubMed ID: 29665313
[TBL] [Abstract][Full Text] [Related]
60. Lipopolysaccharide (LPS)-Induced Biliary Epithelial Cell NRas Activation Requires Epidermal Growth Factor Receptor (EGFR).
Trussoni CE; Tabibian JH; Splinter PL; O'Hara SP
PLoS One; 2015; 10(4):e0125793. PubMed ID: 25915403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
